Predicting childhood chronic kidney disease severity in infants with posterior urethral valve: a critical analysis of creatinine values in the first year of life

2021 ◽  
Author(s):  
Charlotte Q. Wu ◽  
Emily S. Blum ◽  
Dattatraya Patil ◽  
H. Stella Shin ◽  
Edwin A. Smith
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Severity ◽  
Critical Analysis ◽  
Posterior Urethral Valve ◽  
First Year ◽  
Urethral Valve ◽  
First Year Of Life

Serum levels and activity of indoleamine2,3-dioxygenase and tryptophanyl-tRNA synthetase and their association with disease severity in patients with chronic kidney disease

Biomarkers ◽  
2013 ◽  
Vol 18 (5) ◽  
pp. 379-385 ◽  
Author(s):  
Yu-Shi Bao ◽  
Ying Ji ◽  
Shi-Lei Zhao ◽  
Lin-Lin Ma ◽  
Ru-Juan Xie ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Severity ◽  
Serum Levels ◽  
Trna Synthetase

Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First Year Post-Liver Transplantation

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Pauline Maurel ◽  
Aurélie Prémaud ◽  
Paul Carrier ◽  
Marie Essig ◽  
Louise Barbier ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Liver Transplantation ◽  
Risk Factor ◽  
Kidney Disease ◽  
First Year ◽  
Disease Occurrence

scholarly journals Stability of Target Hemoglobin Levels during the First Year of Epoetin Treatment in Patients with Chronic Kidney Disease

2007 ◽  
Vol 2 (5) ◽  
pp. 938-946 ◽  
Author(s):  
Luca De Nicola ◽  
Giuseppe Conte ◽  
Paolo Chiodini ◽  
Bruno Cianciaruso ◽  
Andrea Pota ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
First Year

scholarly journals Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status

2018 ◽  
Vol 1 (4) ◽  
pp. e00029 ◽  
Author(s):  
Ellen Berni ◽  
Nicholas Pritchard ◽  
Sara Jenkins-Jones ◽  
Philip Ambery ◽  
Meena Jain ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
Disease Severity ◽  
Hospital Admissions ◽  
Diabetes Status ◽  
Severe Infections

scholarly journals Butyrate producing microbiota are reduced in chronic kidney diseases

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bei Gao ◽  
Adarsh Jose ◽  
Norma Alonzo-Palma ◽  
Taimur Malik ◽  
Divya Shankaranarayanan ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Gut Microbiota ◽  
Disease Severity ◽  
Kidney Diseases ◽  
Health Concern ◽  
Chronic Kidney Diseases ◽  
Component Systems ◽  
Advanced Stages ◽  
Two Component Systems

AbstractChronic kidney disease is a major public health concern that affects millions of people globally. Alterations in gut microbiota composition have been observed in patients with chronic kidney disease. Nevertheless, the correlation between the gut microbiota and disease severity has not been investigated. In this study, we performed shot-gun metagenomics sequencing and identified several taxonomic and functional signatures associated with disease severity in patients with chronic kidney disease. We noted that 19 microbial genera were significantly associated with the severity of chronic kidney disease. The butyrate-producing bacteria were reduced in patients with advanced stages of chronic kidney diseases. In addition, functional metagenomics showed that two-component systems, metabolic activity and regulation of co-factor were significantly associated with the disease severity. Our study provides valuable information for the development of microbiota-oriented therapeutic strategies for chronic kidney disease.

scholarly journals Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor drugs: Assessment of safety in Fasting Diabetics

2021 ◽  
Vol 25 (1) ◽  
pp. 53-59
Author(s):  
Muhammad Imran Hasan Khan ◽  
Salman Shakeel ◽  
Usama Azhar ◽  
Aqsa Javaid ◽  
Faiqa Ijaz Khan
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Bitter Taste ◽  
First Year ◽  
Advanced Chronic Kidney Disease ◽  
Sodium Glucose Cotransporter

Introduction: Ramadan is a holy month and the majority of Muslims fast in it, without considering background illnesses. SGLT-2 drugs were available for Pakistani patients recently, and this was the first year to fast in their presence.Objectives: To assess the risk of hypoglycemia in fasting diabetics using SGLT-2 drugs, comparing it with Sulphonylurea (SU) drugs. Also, a change in HbA1c and eGFR was checked. Hence, evidence was collected to recommend their use in fasting Diabetics with safety. Material and Methods: A total of 5500 patients from three different sites were included. Only 500 fulfilled the criteria of inclusion. Pregnant, lactating, advanced Chronic Kidney Disease (CKD), and those recording hypoglycemia frequently were not included. Ages between 20 to 70 years, HbA1c between 7 to 11, and patients taking SU or SGLT-2 were included. Conclusion: The eGFR was comparable in both groups post-Ramadan. HbA1c was significantly reduced in the SGLT-2 group. Bitter taste and thirst were common with the SU group. Hypoglycemia was comparable in both groups. We concluded that SGLT-2 drugs were safe during Ramadan, and caused more HbA1c reduction.

scholarly journals Cardiovascular outcomes following percutaneous coronary intervention with drug-eluting balloons in chronic kidney disease: a retrospective analysis

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Michael Jonas ◽  
Maayan Kagan ◽  
Gal Sella ◽  
Dan Haberman ◽  
Gil Chernin
Keyword(s):  
Chronic Kidney Disease ◽  
Percutaneous Coronary Intervention ◽  
Kidney Disease ◽  
Retrospective Analysis ◽  
Coronary Intervention ◽  
Target Lesion ◽  
First Year ◽  
Anti Platelet Therapy ◽  
Percutaneous Coronary ◽  
Drug Eluting

Abstract Background Chronic kidney disease (CKD) is associated with poorer outcomes following percutaneous coronary intervention (PCI) with drug-eluting stents. Drug-eluting balloons are used for in-stent restenosis and selected cases of de-novo coronary lesions. Little is known regarding the outcomes of individuals with CKD who undergo PCI with drug-eluting balloons. The goal of this study was to assess outcomes of PCI with drug-eluting balloons in individuals with CKD. Methods In a retrospective analysis, outcomes of PCI with drug-eluting balloons were compared between 101 patients with CKD and 261 without CKD. CKD was defined as estimated glomerular filtration rate < 60 ml/min/1.73m2. We compared demographics, procedure data and clinical outcomes in the first and second years following the procedure. Results Rates of major adverse cardiac events (MACE) and myocardial infarction were higher in patients with than without CKD: 23.8% vs. 13.8%, P < 0.005 and 15.9% vs. 3.8%, P < 0.001, respectively. Rates of target lesion revascularization were similar, 14.9 and 11.5%, respectively, P = 0.4. Shorter duration of dual anti-platelet therapy was observed among patients with than without CKD (10.0 + 3.4 vs. 10.9 + 3.7 months, P < 0.05). First-year hemorrhage episodes were similar in the two groups (0.08 ± 0.4 and 0.03 ± 0.2, respectively, P = 0.2). In a multivariate regression analysis, CKD was associated with increased risks of first year MACE (OR 2.1; 95% confidence interval 1.0-4.3, P < 0.001). Conclusions PCI with drug-eluting balloons was associated with increased cardiovascular morbidity and mortality in patients with than without CKD. However, rates of target lesion revascularization were similar in the two groups. Shorter duration of dual anti-platelet therapy was observed in the CKD group.

MO471USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A NEW APPROACH

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Rafael Del Pozo Alvarez ◽  
Teresa Vázquez ◽  
Dolores Martínez Esteban ◽  
Daniel Gaitan Roman ◽  
Alicia Moreno Ortiz ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Function ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
First Year ◽  
Ventricular Ejection Fraction ◽  
Long Term Outcome ◽  
Number Of Visits

Abstract Background and Aims Neprilysin inhibition (NEPi) combined with a renin-angiotensin system (RAS) blocker has been shown to play an important role among patients with heart failure (HF), whose main cause of inpatient admission is congestion, reducing effectively HF hospitalization and cardiovascular death. These benefits stem from NEPi being a natriuresis and diuresis factor while RAS, which activates subsequently, staying blocked. Thanks to this, sacubitril/valsartan is a promising tool targeting patients with chronic kidney disease (CKD) and HF, which frequently coexist and lead one to the other, challenging their management. There is evidence NEPi-RASb may be beneficial in this population but long-term outcome still lacks. The primary aim is to analyse potential improvement in HF and advanced CKD. Secondary, to evaluate the tolerability and safety profile in this population. Method A prospective observational study, conducted from October 2016 to December 2020. Twenty-five patients were included meeting the following criteria: diagnosis of HF plus reduced left ventricular ejection fraction (LVEF) and New York Heart Association (NYHA) functional class of II-IV with indication of sacubitril/valsartan, and CKD stages 3-4. All of them were followed periodically by a Nephrologist at our Department. Results The male:women ratio was 4:21, with a mean age of 73.2 ± 5.9 years. All patients had diagnosed hypertension, 32% type 2 diabetes, and 92% dyslipidemia. By December 2020, seven patients had completed three-year follow-up, whereas 17 were followed successfully through one year of treatment. Six patients died during the study (50% due to cardiovascular event, none due to renal malfunction), another discontinued treatment due to hypotension, and no patient started renal replacement therapy. The median of the studied time of treatment was 31 months (IQR 23.5 - 35). Cardiac and renal characteristics are listed in Table 1. At first year a significant improvement in LVEF was found (p=0.018). Although it is observed a tendency to this enhancement at second and third years, statistical analysis was not significative, arguably because a limited sample. Nonetheless, the number of visits to the Emergency Department (ED) regarding congestion symptoms were significantly reduced at these periods. More interesting, kidney function improved at first year when comparing serum creatinine (p=0.043) and eGFR (p=0.008), and this improvement stays in the long term at second and third years (p=0.019, p=0.046 respectively). There were no significant changes in potassium nor in blood pressure, still urine protein excretion was significantly higher at third year (p=0.043), understandable possibly due to hyperfiltration mechanisms and diabetic nephropathy progression. Conclusion Sacubitril/valsartan showed a long-term improvement in cardiac and kidney function, explaining a reduction in the number of visits to ED due to congestion and eventually a better quality of life. Besides, the improvement in kidney function cannot be totally understood in the context of enhanced LVEF at first year as this effect fades with time. Future research should explore this line.

Sign in / Sign up

Export Citation Format

Share Document